85 related articles for article (PubMed ID: 19937676)
1. A novel method in order to evaluate the efficacies and the safeties of new drugs for hepatocellular carcinoma with loss of transforming growth factor-beta signaling.
Moriguchi H
Hepatology; 2009 Dec; 50(6):2050-1; author reply 2051. PubMed ID: 19937676
[No Abstract] [Full Text] [Related]
2. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling.
Lin L; Amin R; Gallicano GI; Glasgow E; Jogunoori W; Jessup JM; Zasloff M; Marshall JL; Shetty K; Johnson L; Mishra L; He AR
Oncogene; 2009 Feb; 28(7):961-72. PubMed ID: 19137011
[TBL] [Abstract][Full Text] [Related]
3. Transforming growth factor-β as a therapeutic target in hepatocellular carcinoma.
Giannelli G; Villa E; Lahn M
Cancer Res; 2014 Apr; 74(7):1890-4. PubMed ID: 24638984
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib: new indication. For some patients with liver cancer.
Prescrire Int; 2009 Apr; 18(100):59. PubMed ID: 19585718
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of transforming growth factor beta receptor type III in hepatocellular carcinoma is not directly associated with genetic alterations or loss of heterozygosity.
Bae HJ; Eun JW; Noh JH; Kim JK; Jung KH; Xie HJ; Park WS; Lee JY; Nam SW
Oncol Rep; 2009 Sep; 22(3):475-80. PubMed ID: 19639191
[TBL] [Abstract][Full Text] [Related]
6. STAT3 inhibition reduces toxicity of oncolytic VSV and provides a potentially synergistic combination therapy for hepatocellular carcinoma.
Marozin S; Altomonte J; Muñoz-Álvarez KA; Rizzani A; De Toni EN; Thasler WE; Schmid RM; Ebert O
Cancer Gene Ther; 2015 Jun; 22(6):317-25. PubMed ID: 25930184
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib in hepatocellular carcinoma: separating the hype from the hope.
Kelley RK; Venook AP
J Clin Oncol; 2008 Dec; 26(36):5845-8. PubMed ID: 19029408
[No Abstract] [Full Text] [Related]
8. New drugs for the treatment of hepatocellular carcinoma.
Boucher E; Forner A; Reig M; Bruix J
Liver Int; 2009 Jan; 29 Suppl 1():148-58. PubMed ID: 19207980
[TBL] [Abstract][Full Text] [Related]
9. Successful topical treatment of sorafenib-induced hand-foot skin reaction in a child with hepatocellular carcinoma.
Hütten M; Lassay L; Sachs B; Deutz P; Mertens R; Baron JM; Merk HF; Ott H
Pediatr Dermatol; 2009; 26(3):349-50. PubMed ID: 19706105
[TBL] [Abstract][Full Text] [Related]
10. Hyperkeratosis of nipple skin during sorafenib treatment.
Frigerio M; Santi V; Di Micoli A; Trevisani F
Dig Liver Dis; 2009 Aug; 41(8):611. PubMed ID: 19303375
[No Abstract] [Full Text] [Related]
11. Clinical trials of note. Sorafenib as adjuvant treatment in the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM).
Printz C
Cancer; 2009 Oct; 115(20):4646. PubMed ID: 19806596
[No Abstract] [Full Text] [Related]
12. Portal vein tumor thrombosis revascularization during sorafenib treatment for hepatocellular carcinoma.
Novi M; Lauritano EC; Piscaglia AC; Barbaro B; Zocco MA; Pompili M; Gasbarrini A
Am J Gastroenterol; 2009 Jul; 104(7):1852-4. PubMed ID: 19574982
[No Abstract] [Full Text] [Related]
13. Localized dyskeratotic plaque with milia associated with sorafenib.
Chappell JA; Burkemper NM; Semchyshyn N
J Drugs Dermatol; 2009 Jun; 8(6):573-6. PubMed ID: 19537383
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of non-islet cell tumor hypoglycemia in hepatocellular carcinoma with doxorubicin.
Kampitak T
Cancer Chemother Pharmacol; 2008 Oct; 62(5):929-30. PubMed ID: 18278497
[No Abstract] [Full Text] [Related]
15. Less Smad2 is good for you! A scientific update on coffee's liver benefits.
Gressner OA
Hepatology; 2009 Sep; 50(3):970-8. PubMed ID: 19610047
[TBL] [Abstract][Full Text] [Related]
16. [The treatment of hepatocellular carcinoma. New developments].
Kuiken SD; van Delden OM; Richel DJ; Jansen PL
Ned Tijdschr Geneeskd; 2009 Apr; 153(14):668-72. PubMed ID: 19425326
[No Abstract] [Full Text] [Related]
17. A new approach to therapy for hepatocellular carcinoma?
Harrison SA; Di Bisceglie AM
Hepatology; 2003 Feb; 37(2):471-3. PubMed ID: 12540798
[No Abstract] [Full Text] [Related]
18. Chemotherapy for advanced hepatocellular carcinoma.
Han KH; Park JY
J Gastroenterol Hepatol; 2008 May; 23(5):682-4. PubMed ID: 18410601
[No Abstract] [Full Text] [Related]
19. Transforming growth factor beta and the liver.
Bissell DM; Roulot D; George J
Hepatology; 2001 Nov; 34(5):859-67. PubMed ID: 11679955
[No Abstract] [Full Text] [Related]
20. Thalidomide-induced severe facial erythema in a patient with hepatocellular carcinoma.
Chiou CC; Shih IH; Chang YC; Lee JC; Kuo SC; Hong HS; Yang CH
Int J Clin Pract; 2007 Aug; 61(8):1415-7. PubMed ID: 17627717
[No Abstract] [Full Text] [Related]
[Next] [New Search]
